Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POSDINEMAB (JNJ-63733657) in Early Alzheimer's Disease
2022-501188-42-00Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing POSDINEMAB arm with Placebo arm (2 arms). Primary endpoint: Change from baseline on iADRS total score at week 104. Started Nov 2022; status: completed.
02
Drugs
posidinemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2022-501188-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501188-42-00.